Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix

Agnieszka Siejka, Andrew V Schally, Norman L Block, Nektarios Barabutis

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

OBJECTIVE: To assess the mechanism by which the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix exerts its effects in men with benign prostatic hyperplasia (BPH), as it produces a long-lasting improvement in lower urinary tract symptoms that is only partly accounted for by the transient reduction in testosterone levels, and the beneficial results could be due to direct inhibitory effects of cetrorelix on the prostate exerted through prostatic LHRH receptors. MATERIALS AND METHODS: Using the BPH-1 cell line we evaluated the effects of cetrorelix in vitro on the proliferation and the expression of receptors for LHRH, epidermal growth factor (EGF), α1A-adrenergic receptor, STAT-3 transcription factor and the response to growth factors insulin-like growth factor (IGF)-1 and -II and fibroblast growth factor (FGF)-2. RESULTS: There was expression of LHRH receptors in the human BPH-1 cell line. Cetrorelix had inhibitory effects on the proliferation rate of BPH-1 cells, also reflected by the decrease in the expression of the proliferating cell nuclear antigen (PCNA). Cetrorelix inhibited the stimulatory effect of the growth factors IGF-I and -II and FGF-2 on the proliferation of this line. Cetrorelix also downregulated the expression of the receptors for LHRH and EGF, as well as of α1A-adrenergic receptors, and inhibited the activation of the STAT3 transcription factor. CONCLUSIONS: The results show that in vitro cetrorelix can directly inhibit the proliferation rate of the human BPH-1 cell line by counteracting growth factors like IGF-I and -II and FGF-2, and downregulating the LHRH receptor and α-adrenergic receptors, as well as transcription factors.

Original languageEnglish
Pages (from-to)1382-1388
Number of pages7
JournalBJU International
Volume106
Issue number9
DOIs
StatePublished - Nov 1 2010

Fingerprint

Hormone Antagonists
Prostatic Hyperplasia
Gonadotropin-Releasing Hormone
LHRH Receptors
Insulin-Like Growth Factor II
Fibroblast Growth Factor 2
Adrenergic Receptors
Intercellular Signaling Peptides and Proteins
Insulin-Like Growth Factor I
Epidermal Growth Factor
Cell Line
Down-Regulation
STAT Transcription Factors
STAT3 Transcription Factor
Lower Urinary Tract Symptoms
Proliferating Cell Nuclear Antigen
In Vitro Techniques
cetrorelix
Testosterone
Prostate

Keywords

  • α-adrenergic receptor
  • antagonist
  • BPH
  • cetrorelix
  • growth factors
  • LHRH

ASJC Scopus subject areas

  • Urology

Cite this

Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix. / Siejka, Agnieszka; Schally, Andrew V; Block, Norman L; Barabutis, Nektarios.

In: BJU International, Vol. 106, No. 9, 01.11.2010, p. 1382-1388.

Research output: Contribution to journalArticle

@article{33ceaec077514d2baec49eea070b56a4,
title = "Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix",
abstract = "OBJECTIVE: To assess the mechanism by which the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix exerts its effects in men with benign prostatic hyperplasia (BPH), as it produces a long-lasting improvement in lower urinary tract symptoms that is only partly accounted for by the transient reduction in testosterone levels, and the beneficial results could be due to direct inhibitory effects of cetrorelix on the prostate exerted through prostatic LHRH receptors. MATERIALS AND METHODS: Using the BPH-1 cell line we evaluated the effects of cetrorelix in vitro on the proliferation and the expression of receptors for LHRH, epidermal growth factor (EGF), α1A-adrenergic receptor, STAT-3 transcription factor and the response to growth factors insulin-like growth factor (IGF)-1 and -II and fibroblast growth factor (FGF)-2. RESULTS: There was expression of LHRH receptors in the human BPH-1 cell line. Cetrorelix had inhibitory effects on the proliferation rate of BPH-1 cells, also reflected by the decrease in the expression of the proliferating cell nuclear antigen (PCNA). Cetrorelix inhibited the stimulatory effect of the growth factors IGF-I and -II and FGF-2 on the proliferation of this line. Cetrorelix also downregulated the expression of the receptors for LHRH and EGF, as well as of α1A-adrenergic receptors, and inhibited the activation of the STAT3 transcription factor. CONCLUSIONS: The results show that in vitro cetrorelix can directly inhibit the proliferation rate of the human BPH-1 cell line by counteracting growth factors like IGF-I and -II and FGF-2, and downregulating the LHRH receptor and α-adrenergic receptors, as well as transcription factors.",
keywords = "α-adrenergic receptor, antagonist, BPH, cetrorelix, growth factors, LHRH",
author = "Agnieszka Siejka and Schally, {Andrew V} and Block, {Norman L} and Nektarios Barabutis",
year = "2010",
month = "11",
day = "1",
doi = "10.1111/j.1464-410X.2010.09215.x",
language = "English",
volume = "106",
pages = "1382--1388",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix

AU - Siejka, Agnieszka

AU - Schally, Andrew V

AU - Block, Norman L

AU - Barabutis, Nektarios

PY - 2010/11/1

Y1 - 2010/11/1

N2 - OBJECTIVE: To assess the mechanism by which the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix exerts its effects in men with benign prostatic hyperplasia (BPH), as it produces a long-lasting improvement in lower urinary tract symptoms that is only partly accounted for by the transient reduction in testosterone levels, and the beneficial results could be due to direct inhibitory effects of cetrorelix on the prostate exerted through prostatic LHRH receptors. MATERIALS AND METHODS: Using the BPH-1 cell line we evaluated the effects of cetrorelix in vitro on the proliferation and the expression of receptors for LHRH, epidermal growth factor (EGF), α1A-adrenergic receptor, STAT-3 transcription factor and the response to growth factors insulin-like growth factor (IGF)-1 and -II and fibroblast growth factor (FGF)-2. RESULTS: There was expression of LHRH receptors in the human BPH-1 cell line. Cetrorelix had inhibitory effects on the proliferation rate of BPH-1 cells, also reflected by the decrease in the expression of the proliferating cell nuclear antigen (PCNA). Cetrorelix inhibited the stimulatory effect of the growth factors IGF-I and -II and FGF-2 on the proliferation of this line. Cetrorelix also downregulated the expression of the receptors for LHRH and EGF, as well as of α1A-adrenergic receptors, and inhibited the activation of the STAT3 transcription factor. CONCLUSIONS: The results show that in vitro cetrorelix can directly inhibit the proliferation rate of the human BPH-1 cell line by counteracting growth factors like IGF-I and -II and FGF-2, and downregulating the LHRH receptor and α-adrenergic receptors, as well as transcription factors.

AB - OBJECTIVE: To assess the mechanism by which the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix exerts its effects in men with benign prostatic hyperplasia (BPH), as it produces a long-lasting improvement in lower urinary tract symptoms that is only partly accounted for by the transient reduction in testosterone levels, and the beneficial results could be due to direct inhibitory effects of cetrorelix on the prostate exerted through prostatic LHRH receptors. MATERIALS AND METHODS: Using the BPH-1 cell line we evaluated the effects of cetrorelix in vitro on the proliferation and the expression of receptors for LHRH, epidermal growth factor (EGF), α1A-adrenergic receptor, STAT-3 transcription factor and the response to growth factors insulin-like growth factor (IGF)-1 and -II and fibroblast growth factor (FGF)-2. RESULTS: There was expression of LHRH receptors in the human BPH-1 cell line. Cetrorelix had inhibitory effects on the proliferation rate of BPH-1 cells, also reflected by the decrease in the expression of the proliferating cell nuclear antigen (PCNA). Cetrorelix inhibited the stimulatory effect of the growth factors IGF-I and -II and FGF-2 on the proliferation of this line. Cetrorelix also downregulated the expression of the receptors for LHRH and EGF, as well as of α1A-adrenergic receptors, and inhibited the activation of the STAT3 transcription factor. CONCLUSIONS: The results show that in vitro cetrorelix can directly inhibit the proliferation rate of the human BPH-1 cell line by counteracting growth factors like IGF-I and -II and FGF-2, and downregulating the LHRH receptor and α-adrenergic receptors, as well as transcription factors.

KW - α-adrenergic receptor

KW - antagonist

KW - BPH

KW - cetrorelix

KW - growth factors

KW - LHRH

UR - http://www.scopus.com/inward/record.url?scp=77954398049&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954398049&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2010.09215.x

DO - 10.1111/j.1464-410X.2010.09215.x

M3 - Article

C2 - 20151966

AN - SCOPUS:77954398049

VL - 106

SP - 1382

EP - 1388

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 9

ER -